Key Points
- CEO Mark Ordan sold 23,000 shares on December 15 at an average price of $22.41 for a total of $515,430, trimming his stake by 7.06% to 302,805 shares valued at roughly $6.79 million.
- Pediatrix reported a quarterly beat with $0.67 EPS vs. $0.46 expected and revenue of $492.88 million (down 3.6% YoY), while analysts expect about $1.38 EPS for the current fiscal year.
- The stock traded at $21.87 (down $0.70), with a market cap of $1.88 billion, a P/E of 11.48 and a 52-week range of $11.84–$24.99; the consensus rating is a "Moderate Buy" with a $21.00 price target.
Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) CEO Mark Ordan sold 23,000 shares of Pediatrix Medical Group stock in a transaction on Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the transaction, the chief executive officer owned 302,805 shares in the company, valued at approximately $6,785,860.05. This trade represents a 7.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Pediatrix Medical Group Price Performance
MD stock traded down $0.70 during trading on Thursday, reaching $21.87. The company's stock had a trading volume of 42,312 shares, compared to its average volume of 803,766. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.65. The company's fifty day moving average is $20.73 and its 200-day moving average is $16.92. The company has a market capitalization of $1.88 billion, a P/E ratio of 11.48 and a beta of 0.77. Pediatrix Medical Group, Inc. has a 1 year low of $11.84 and a 1 year high of $24.99.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.46 by $0.21. Pediatrix Medical Group had a return on equity of 20.45% and a net margin of 8.44%.The business had revenue of $492.88 million for the quarter, compared to the consensus estimate of $476.45 million. During the same period in the previous year, the business earned $0.44 earnings per share. The business's revenue was down 3.6% on a year-over-year basis. On average, research analysts expect that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pediatrix Medical Group
A number of institutional investors and hedge funds have recently modified their holdings of MD. Cambria Investment Management L.P. raised its holdings in Pediatrix Medical Group by 25.0% during the 3rd quarter. Cambria Investment Management L.P. now owns 38,207 shares of the company's stock valued at $640,000 after buying an additional 7,641 shares during the period. Hancock Whitney Corp increased its position in Pediatrix Medical Group by 30.0% during the third quarter. Hancock Whitney Corp now owns 33,701 shares of the company's stock valued at $565,000 after acquiring an additional 7,772 shares during the last quarter. Caxton Associates LLP raised its stake in shares of Pediatrix Medical Group by 92.4% in the third quarter. Caxton Associates LLP now owns 31,585 shares of the company's stock valued at $529,000 after acquiring an additional 15,167 shares during the period. Verition Fund Management LLC raised its stake in shares of Pediatrix Medical Group by 4.4% in the third quarter. Verition Fund Management LLC now owns 25,408 shares of the company's stock valued at $426,000 after acquiring an additional 1,066 shares during the period. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Pediatrix Medical Group by 55.4% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company's stock worth $19,150,000 after acquiring an additional 407,780 shares during the last quarter. Hedge funds and other institutional investors own 97.71% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have issued reports on MD. Wall Street Zen raised shares of Pediatrix Medical Group from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 4th. Truist Financial raised their target price on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the company a "hold" rating in a research note on Monday, November 10th. Zacks Research upgraded shares of Pediatrix Medical Group from a "hold" rating to a "strong-buy" rating in a report on Friday, November 21st. Weiss Ratings reissued a "hold (c+)" rating on shares of Pediatrix Medical Group in a report on Monday. Finally, Leerink Partners raised their price objective on Pediatrix Medical Group from $14.50 to $17.00 and gave the company a "market perform" rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.
View Our Latest Stock Report on MD
Pediatrix Medical Group Company Profile
(
Get Free Report)
Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
